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Studies	in	rodents	have	shown	that	male	sexual	function	can	be	disrupted	by	fetal	or	neonatal	administration	
of	compounds	that	alter	endocrine	homeostasis,	such	as	the	synthetic	nonsteroidal	estrogen	diethylstilbestrol	
(DES).	Although	the	molecular	basis	for	this	effect	remains	unknown,	estrogen	receptors	likely	play	a	critical	
role	in	mediating	DES-induced	infertility.	Recently,	we	showed	that	the	orphan	nuclear	receptor	small	het-
erodimer	partner	(Nr0b2),	which	is	both	a	target	gene	and	a	transcriptional	repressor	of	estrogen	receptors,	
controls	testicular	function	by	regulating	germ	cell	entry	into	meiosis	and	testosterone	synthesis.	We	therefore	
hypothesized	that	some	of	the	harmful	effects	of	DES	on	testes	could	be	mediated	through	Nr0b2.	Here,	we	
present	data	demonstrating	that	Nr0b2	deficiency	protected	mice	against	the	negative	effects	of	DES	on	testis	
development	and	function.	During	postnatal	development,	Nr0b2-null	mice	were	resistant	to	DES-mediated	
inhibition	of	germ	cell	differentiation,	which	may	be	the	result	of	interference	by	Nr0b2	with	retinoid	signals	
that	control	meiosis.	Adult	Nr0b2-null	male	mice	were	also	protected	against	the	effects	of	DES;	however,	we	
suggest	that	this	phenomenon	was	due	to	the	removal	of	the	repressive	effects	of	Nr0b2	on	steroidogenesis.	
Together,	these	data	demonstrate	that	Nr0b2	plays	a	critical	role	in	the	pathophysiological	changes	induced	
by	DES	in	the	mouse	testis.
Introduction
The small heterodimer partner (Shp; referred to herein as Nr0b2) 
is mainly known for its role in the liver, where it is involved in the 
feedback inhibition of bile acid synthesis (1–4). The functions of 
Nr0b2 have been linked to its ability to repress the transcriptional 
activity of other nuclear receptors (NRs) such as the liver homolog-1 
(Lrh-1; referred to herein as Nr5a2; refs. 1, 3) and the estrogen 
receptors (Erα/β; referred to herein as Nr3a1/2; ref. 5). In addition 
to the liver, Nr0b2 has also been shown to be expressed in the testis 
(6–8). We have recently demonstrated that Nr0b2 interacts with 
retinoid signaling in the testis, which leads to germ cell entry in 
meiosis (8). Moreover, Nr0b2 controls testosterone synthesis inde-
pendently of the hypothalamus/pituitary axis (8). These results 
suggest that in the testis, Nr0b2 interferes with several signaling 
pathways important for reproductive biology.
In recent years, a causal link between in utero and/or neonatal 
exposure to molecules that alter endocrine functions and the devel-
opment of genital tract abnormalities, such as cryptorchidism, 
hypospadias, and impaired spermatogenesis, has emerged from 
studies in rodents. Most of these endocrine disrupters (EDs) exert 
some estrogenic and/or antiandrogenic activities (9). However, these 
molecules are rarely pure agonists or antagonists and can induce sev-
eral signaling pathways. A good example is diethylstilbestrol (DES), 
known to induce reproductive disorders (10). DES has been shown 
to activate several members of the NR family, such as the Er and 
the estrogen-related receptors α/β/γ (Errα/β/γ; referred to herein as 
Nr3b1, Nr3b2, and Nr3b3, respectively; refs. 11–14). Even though 
the exact molecular basis remains unknown, the use of transgenic 
models suggests that Ers are involved (15–18). Moreover, some stud-
ies show similar changes in testicular gene expression induced by 
estradiol and DES (15). Other data, however, suggest differences in 
the molecular targets introduced by estradiol and DES (19).
Interestingly, Nr0b2 is a direct target gene of both the Ers (20) and 
the Errs (21) and inhibits their transcriptional activity (6, 22, 23). We 
hence hypothesized that part of the testicular effects of DES, both 
estrogen dependent and independent, could be mediated through 
Nr0b2. Using exposure to DES, to the pure estrogen agonist estradiol 
benzoate (EB), and to Er antagonist ICI 182,780 (referred to herein as 
ICI), we demonstrate here that Nr0b2 deficiency protects male mice 
against the harmful estrogenic and nonestrogenic effects of DES. 
During postnatal development, Nr0b2-null mice were more resistant 
to the DES-mediated inhibition of germ cell differentiation, which is 
explained by our finding that Nr0b2 interfered with retinoid signals 
that control meiosis. In adult Nr0b2-null male mice, however, protec-
tion against the negative effects of DES was caused, at least in part, 
by the removal of Nr0b2-repressive effects on steroidogenesis. These 
data demonstrate that Nr0b2 plays a critical role in the pathophysi-
ological changes induced by EB and DES in the testis.
Results
Estrogenic compounds induce testicular expression of Nr0b2. In order to 
identify a potential molecular link between Nr0b2 and the estab-
lished negative effects of DES on male fertility, we monitored 
Nr0b2 expression at different time points during which treat-
ment with DES is known to induce reproductive abnormalities 
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(P1–P5). mRNA analyses demonstrated that Nr0b2 was expressed 
in the whole testis at these ages (Supplemental Figure 1A; supple-
mental material available online with this article; doi:10.1172/
JCI38521DS1). Moreover, the mRNA of the NRs known to be tar-
gets of DES, such as Nr3a1, Nr3a2, and Nr3b1/2/3, were expressed 
in the testis (Supplemental Figure 1A). Treatment with DES caused 
higher mRNA accumulation of Nr0b2 in testes of P10 Nr0b2 wild-
type (Nr0b2+/+) male mice (Figure 1A). In the adult testis, a dose-
dependent increase in Nr0b2 mRNA was also observed upon DES 
administration. Interestingly, similar effects on Nr0b2 mRNA 
levels were observed using the pure estrogen EB (Supplemental 
Figure 1B), which suggests that the regulation of Nr0b2 gene was 
caused, at least in part, by the estrogenic effect of DES.
DES has a weak impact on the fertility of Nr0b2-knockout mice. We then 
treated neonatal Nr0b2+/+ and knockout (Nr0b2L–/L–) male mice with 
increasing doses of DES (0–5 μg). Neonatal exposure of Nr0b2+/+ 
males to DES caused a significant 80% decrease in the number 
of pups per litter, whereas it had a lesser impact on litters from 
Nr0b2L–/L– males (Figure 1B). These data were consistent with the 
decreased number of spermatozoa in the epididymis tails of treat-
ed Nr0b2+/+ males, which was much less pronounced in Nr0b2L–/L– 
males (Figure 1C). The weights of testis, epididymis, and semi-
nal vesicles were also more reduced in Nr0b2+/+ than in Nr0b2L–/L– 
male mice exposed to DES (Figure 1D). Consistent with these 
protective effects, the minimal dose of DES at which testis weight 
started to decrease was between 0.75 and 1.5 μg in Nr0b2+/+ males, 
whereas there was almost no effect in Nr0b2L–/L– males (Figure 1D). 
The protection against DES caused by Nr0b2 gene inactivation was 
not a general or systemic effect, as body and liver weights were sim-
ilarly affected by DES in both genotypes (Figure 1D).
Even though DES belongs to the group of EDs with estrogen 
activity, it can also activate other signaling pathways (24). Neo-
natal administration of the pure estrogen, EB, to Nr0b2+/+ males 
decreased the adult weights of the testis, epididymis, and seminal 
vesicles (Supplemental Figure 1C). As for DES administration, 
the Nr0b2L–/L– males were significantly protected from the unde-
sired effects of EB compared with Nr0b2+/+ males. The number of 
spermatozoa decreased in the epididymis tails of treated Nr0b2+/+ 
Figure 1
Nr0b2 deficiency protects male mice against DES-induced abnormalities. (A) Nr0b2 mRNA levels in whole testes of P10 Nr0b2+/+ and Nr0b2L–/L– 
males exposed to 0.75 μg DES (n = 6), and in whole testes of 10-week-old males neonatally exposed to 0, 0.75, and 5 μg DES (n = 3–5). Values 
were normalized to β-actin. (B) Each male was bred with 5 C57BL/6J females to analyze the number of pups per litter. (C and D) Spermatozoa 
count in the tail of epididymis (C) and whole body weight as well as weights of testis, epididymis, seminal vehicles, and liver normalized to body 
weight (D) of 10-week-old Nr0b2+/+ and Nr0b2L–/L– males neonatally exposed to 0, 0.35, 0.5, 0.75, 1.5, and 5 μg DES (n = 6–14 per group). 
*P < 0.05 versus vehicle; #P < 0.05 versus Nr0b2+/+ given the same DES dose.
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males, whereas no effect of EB was observed in Nr0b2L–/L– males 
(Supplemental Figure 1D). These effects of DES might be in 
part mediated by the Ers, as the use of the Er antagonist ICI on 
Nr0b2+/+ males was able to reverse part of the impact of DES on the 
decreased count of spermatozoa as well as on the decrease in organ 
weights (Supplemental Figure 1, E and F).
Nr0b2 deficiency protects mice from DES-induced germ cell death. In 
10-week-old adult Nr0b2+/+ mice exposed to 5 μg DES, the testes 
showed major morphological alterations, as reflected by the absence 
of germ cells in several tubules (Figure 2A). Conversely, even at this 
high dose, Nr0b2L–/L– males did not show apparent abnormalities. 
The use of cell type–specific markers (25) allowed us to determine 
that postmeiotic cells were the most affected cell population in 
DES-treated Nr0b2+/+ mice, as reflected by the decreased number 
of Smad6-positive cells (Figure 2B and Supplemental Figure 2A). 
On the contrary, no difference was observed in the number of Ser-
toli and premeiotic/early meiotic germinal cells (as determined by 
staining for Tubulin3 and Cyclin-A1, respectively; Figure 2B).
We then assessed potential changes in the rate of proliferation. No 
significant change in the expression of the proliferation marker Ki-67 
or in the accumulation of PCNA was observed between untreated 
or DES-treated Nr0b2+/+ and Nr0b2L–/L– males (Supplemental Figure 
2B). However, DES induced a significant increase in apoptotic cells 
in the testes of Nr0b2+/+ mice starting at the 0.75-μg dose, as deter-
mined by TUNEL analysis (Figure 3, A and B). The increased apopto-
sis in Nr0b2+/+ testis corroborated with the increased accumulation of 
active caspase-3 (Figure 3C). On the contrary, Nr0b2L–/L– males were 
protected from the increased apoptosis induced by DES (Figure 3). 
In a similar experiment, neonatal exposure of mice to EB resulted 
in germ cell loss caused by an increased number of apoptotic cells 
in adult Nr0b2+/+ mice, whereas Nr0b2L–/L– males were also protected 
from apoptosis induced by EB (Supplemental Figure 2, C and D).
Nr0b2 reduces testosterone levels after DES exposure. Germ cell death 
has previously been associated with androgen withdrawal (26, 27). 
Consistent with previous data (28, 29), DES induced a decrease in 
testosterone concentrations in Nr0b2+/+ males at as little as 0.75 μg 
(Figure 4A). This effect was further pronounced at 5 μg DES. The 
inhibition of testosterone was associated with a decrease in mRNA 
levels of Star, Cyp11a1, and Cyp17a1, which are critically involved in 
steroidogenesis (Figure 4B). Interestingly, Nr0b2L–/L– males seemed 
to be protected from these effects of DES, as testosterone concen-
trations as well as Star, Cyp11a1, and Cyp17a1 mRNA levels were 
not affected (Figure 4, A and B). No effect of DES was observed on 
mRNA accumulation of the androgen receptor Nr3c4 in Nr0b2+/+ or 
Nr0b2L–/L– testes (Figure 4C). The decrease in testosterone was also 
consistent with the reduction in mRNA abundance of the andro-
gen-dependent genes Pem and Osp in Nr0b2+/+ males. In addition to 
the impact of DES on the androgen pathway, we analyzed its impact 
on Er target genes. The mRNA accumulation of Nr3a1 and insulin-
like–3 (Insl3) decreased in Nr0b2+/+ testes, as expected, whereas this 
effect of DES was not observed in Nr0b2L–/L– testes (Figure 4C). Also 
as expected, DES had no effect on the accumulation of Nr3a2.
We next analyzed the expression of known regulators of ste-
roidogenesis to identify how Nr0b2 could control steroid synthe-
sis. Regarding the inducers of steroidogenesis, Nr5a2 and the ste-
roidogenic factor–1 (Sf-1, referred to herein as Nr5a1), both known 
targets of Nr0b2, only Nr5a2 expression decreased at 0.75 μg DES 
(Figure 4C). DES had no effect on the expression of dosage-sensi-
Figure 2
DES-induced histological abnormalities caused by loss of postmeiotic cells in Nr0b2+/+ mice. (A) Representative micrographs of H&E-stained 
testes of 10-week-old Nr0b2+/+ and Nr0b2L–/L– mice exposed to vehicle or 5 μg DES (n = 6 per group). The arrow indicates tubules with a slight 
loss of germ cells; the arrowhead indicates tubes with complete loss of germ cells. Original magnification, ×100. (B) Quantification of cells per 
100 seminiferous tubules (n = 4–6) positively stained for markers Smad6 (postmeiotic germ cells), Tubulin3 (Sertoli cells), and Cyclin-A1 (pre- 
and meiotic germ cells). Vehicle-treated mice were arbitrarily set at 100%. *P < 0.05 versus vehicle.
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tive sex reversal, adrenal hypoplasia congenita, critical region on 
the X chromosome, gene 1 (Dax-1, referred to herein as Nr0b1), a 
negative regulator of steroidogenesis (Figure 4C). The use of the Er 
agonist EB, or the antagonist ICI, suggests a significant contribu-
tion of the estrogenic effects of DES on the repression of steroido-
genesis (Supplemental Figure 2, E and F). Indeed, EB exposure 
resulted in a decrease of the intratesticular concentration of tes-
tosterone in Nr0b2+/+ mice. Similar to what we observed after DES 
treatment, we observed no effect on testosterone level in Nr0b2L–/L– 
males after EB exposure. Moreover, ICI exposure reversed the effect 
of DES on testosterone in Nr0b2+/+ males.
To test whether the DES-induced effects on the testis are reg-
ulated at the level of the hypothalamus/pituitary axis, we first 
measured LH and FSH plasma levels. Interestingly, no impact of 
DES on LH or FSH level was observed, which suggests that the 
primary effect of DES occurs at the testicular level (Figure 4D). 
Several studies have demonstrated that estrogen can regulate ste-
roidogenesis directly on the level of the Leydig cell. To confirm this 
hypothesis, we performed some in vitro analyses using the Ma-10 
Leydig cell line. EB and DES increased Nr0b2 mRNA accumulation 
at 12 and 24 hours after treatment, whereas the decrease in the 
mRNA levels of steroidogenic genes such as Star was observed only 
after 24 hours (Figure 4E). Consistent with our previous report 
(8), these results suggest that Nr0b2 might directly repress steroid 
synthesis after DES and/or estrogen treatment.
DES exposure alters neonatal germ cell differentiation through Nr0b2. 
DES was administered close to the beginning of germ cell differen-
tiation (30, 31). To determine an eventual impact of DES exposure 
on germ cell differentiation, we analyzed the testis at P6 or P10. 
At P6, there was no alteration in the expression of genes specific 
for undifferentiated spermatogonia (Oct3/4, Nanos3, and Cyclin-d2; 
Figure 5A). However, in Nr0b2+/+ mice treated with DES, expression 
of transcripts involved in germ cell differentiation (Stra8 and Dmc1) 
was significantly lower. This effect was not observed in the Nr0b2L–/L– 
males. At P10, the accumulation of mRNAs involved in germ cell dif-
ferentiation was still reduced in the testes of Nr0b2+/+ mice exposed 
to DES, an effect that was accompanied by the robust induction of 
specific transcripts of undifferentiated spermatogonia (Figure 5B), 
suggesting an alteration of the relative proportion of undifferenti-
ated versus differentiating spermatogonia following DES admin-
istration in Nr0b2+/+ mice. Moreover, at P10, the meiotic marker 
Cyclin-a1 was found to be decreased by DES treatment, which is con-
Figure 3
Nr0b2 controls DES-induced adult germ cell apoptosis through regulation of testosterone synthesis. (A) Apoptosis in 10-week-old Nr0b2+/+ and 
Nr0b2L–/L– mice exposed to vehicle or 5 μg DES (n = 6 per group), as analyzed by TUNEL staining. Arrowheads denote TUNEL-positive cells. Rep-
resentative micrographs are shown. Original magnification, ×100. (B) Quantification of TUNEL analyses. Shown is the number of positive cells per 
100 seminiferous tubules (n = 4–6). (C) Immunoblot of activate caspase-3 performed on testicular protein extracts of Nr0b2+/+ and Nr0b2L–/L– mice 
exposed to 0 or 5 μg DES (n = 6 per group). Quantification of activated caspase-3 protein accumulation relative to total caspase-3 is shown below; 
vehicle-treated mice were arbitrarily fixed at 100%. *P < 0.05 versus vehicle; #P < 0.05 versus Nr0b2+/+ given the same DES dose.
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sistent with a decreased germ cell differentiation. Again, Nr0b2L–/L– 
testes were not affected. Similar studies using EB instead of DES 
showed that part of the effect of DES is likely mediated by Ers, as 
several genes, including Nanos3, Stra8, Dmc1, Cyclin-a1, Cyclin-d2, 
appeared to be regulated in a similar way (Supplemental Figure 3, 
A and B). Interestingly, some other genes, such as Oct3/4, showed a 
different expression pattern in mice treated with EB compared with 
those treated with DES (compare Figure 5B and Supplemental Fig-
ure 3B). Interestingly, this effect of DES on Oct3/4 expression was 
also inhibited in Nr0b2L–/L– males, which suggests that Nr0b2 is a 
major component of the signaling pathways activated by DES.
Neonatal effect of DES exposure involves apoptosis and estrogenic signal-
ing, but is independent of androgen status. To understand the molecular 
pathways underlying the alteration in germ cell maturation, we ana-
lyzed both proliferation and apoptotic processes in P10 testis. No 
effect was observed on cell proliferation, as suggested by the analysis 
of PCNA protein accumulation (Supplemental Figure 3C). In P10 
mice, DES induced apoptosis, as revealed by increased accumulation 
of the active caspase-3 protein, in Nr0b2+/+ mice (Figure 5C). On the 
contrary, the impact of DES on apoptosis was not observed in the 
testes of Nr0b2L–/L– males. Interestingly, the changes in the number 
of apoptotic cells did not seem to be linked to the androgen status, 
as intratesticular testosterone decreased in both genotypes (Figure 
5D). In fact, DES treatment induced a drastic decrease of the intra-
testicular testosterone in both Nr0b2+/+ and Nr0b2L–/L– males. We also 
analyzed mRNA accumulation of Star and of the androgen-depen-
dent genes Pem and Osp. The expression of these genes was decreased 
following DES exposure in both genotypes (Figure 5E), reflecting the 
decrease of intratesticular androgen levels. As for DES, EB adminis-
tration resulted in a decreased expression of the steroidogenic genes 
Star, Cyp11a1, and Cyp17 (Supplemental Figure 3D). This result sug-
gests that neonatal steroidogenesis, in contrast to that of adult mice, 
is not controlled by Nr0b2, since Nr0b2L–/L– mice showed a profile 
similar to that of Nr0b2+/+ mice (Figure 5, D and E).
Figure 4
Nr0b2 controls DES-induced repression of testosterone synthesis. (A) Plasma and intratesticular testosterone levels in 10-week-old Nr0b2+/+ 
and Nr0b2L–/L– mice exposed to 0, 0.75, or 5 μg DES (n = 10–15 per group). (B) Testicular mRNA expression of Star, Cyp11a1, Hsd3b1, and 
Cyp17a1, normalized to β-actin levels, in whole testes of 10-week-old Nr0b2+/+ and Nr0b2L–/L– mice exposed to 0 or 0.75 μg DES (n = 10–15 
per group). (C) Testicular mRNA expression of Nr3c4, Pem, Osp, Nr3a1, Nr3a2, Insl3, Nr5a2, Nr5a1, and Nr0b1, normalized to β-actin levels, 
in whole testes of 10-week-old Nr0b2+/+ and Nr0b2L–/L– mice exposed to 0 or 0.75 μg DES (n = 10–15 per group). (D) Plasma LH and FSH con-
centration in 10-week-old Nr0b2+/+ and Nr0b2L–/L– mice exposed to 0, 0.75, or 5 μg DES (n = 10–15 per group). (E) mRNA expression of Nr0b2 
and Star normalized to β-actin levels in MA-10 Leydig cells exposed to vehicle, EB, or DES for 12 or 24 hours (n = 6 per group). Vehicle-treated 
mice were arbitrarily fixed at 100%. *P < 0.05 versus vehicle; #P < 0.05 versus Nr0b2+/+ given the same DES dose.
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The impact of DES on the estrogenic pathway was then ana-
lyzed in the testes of Nr0b2L–/L– mice and Nr0b2+/+ littermates. 
No effect of DES was observed on the expression of Nr3a2 (Fig-
ure 5F). However, consistent with the estrogenic effect of DES, 
the expression of known target genes of the Ers (16) — including 
Nr3a1, Insl3, and renin-1 (Ren1) — decreased, whereas the expres-
sion of gene regulated in breast cancer 1 protein (Greb1) increased 
(Figure 5, F and G). For Insl3 and Ren1, the effect of DES was 
similar in Nr0b2+/+ and Nr0b2L–/L– males. On the contrary, the 
impact of DES on the expression of Nr3a1 and Greb1 was lost 
or diminished in Nr0b2L–/L– versus Nr0b2+/+ mice. Similarly, the 
estrogenic target genes Nr3a1, Insl3, and Ren1 were affected by EB 
(Supplemental Figure 3E). These data demonstrated that Nr0b2 
is not involved in the regulation of all the Er target genes, which 
suggests that there might be some compensatory mechanisms 
involving other cofactors of Nr3a1/2.
Nr0b2 mediates part of the neonatal effects of DES through modifica-
tion of histone methylation marks. Previous studies have shown that 
mice lacking the H3K9 histone methyltransferase G9a are sterile, 
with germ cells undergoing apoptosis during the pachytene stage 
(32). G9a is reported to perform H3K9 mono- and dimethylation 
(marked by H3K9me1 and H3K9me2, respectively; refs. 33, 34). 
In view of the Nr0b2-dependent proapoptotic effects of DES on 
germ cells, we wondered whether these effects could be medi-
ated by factors affecting histone methylation, such as G9a (31). 
Interestingly, in testes of DES-treated P10 Nr0b2+/+ animals, the 
H3K9me1/2 marks decreased, whereas they were unaffected in 
Nr0b2L–/L– mice (Figure 6, A and B). This suggests that DES might 
affect G9a expression. Consistent with this hypothesis, testicular 
G9a mRNA and G9a protein expression decreased in Nr0b2+/+ mice 
treated with DES, whereas no effect was observed in the Nr0b2L–/L– 
mice (Figure 6, C and D). The decrease of the transcriptional 
Figure 5
Nr0b2 inhibits neonatal germ cell differentiation in response to DES. Nr0b2+/+ and Nr0b2L–/L– mice were exposed to 0 or 0.75 μg DES. (A and B) 
Testicular mRNA expression of Oct3/4, Nanos3, Cyclin-d2, Stra8, Dmc1, and Cyclin-a1, normalized to β-actin levels, in P6 (A) or P10 (B) mice 
(n = 5–10 per group). (C) Immunoblot of activate caspase-3 on testicular protein extracts (n = 6 per group). Quantification of activate capase-3 
protein accumulation relative to total caspase-3 is also shown. (D) Intratesticular testosterone levels in P10 mice (n = 10–15 per group). (E–G) 
mRNA expression of Star, Pem, and Osp (E); Nr3a1, Nr3a2, Nr3c4, Nr5a2, and Nr0b1 (F); and Insl3, Ren1, and Greb1 (G) in whole testes of 
P10 mice (n = 10–15 per group). Values were normalized to β-actin levels. Vehicle-treated mice were set at 100%. *P < 0.05 versus vehicle; 
#P < 0.05 versus Nr0b2+/+ given the same DES dose.
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repressor G9a following DES administration in Nr0b2+/+ mice was 
also associated with an increase of several G9a target genes (32, 
35), including Akr1c13, Akr1c12, Chst11, 290, 291, 110, Wfdc15a, and 
Iap, as a result of relief of repression (Figure 6E). Conversely, and 
in line with previous studies describing a downregulation of Mei1 
in G9a-null mice (32), mRNA levels of this gene were decreased in 
the Nr0b2+/+ mice treated with DES (Figure 6E). In the Nr0b2L–/L– 
mice, neither a significant effect nor an opposite effect of DES was 
observed on the expression of these genes compared with Nr0b2+/+ 
mice. In Nr0b2+/+ males, the use of EB also induced a clear decrease 
in G9a mRNA levels at P6 and P10, which translated to a robust 
decrease in G9a protein levels (Supplemental Figure 4, A and B). 
The H3K9me2 mark was also decreased by EB in Nr0b2+/+ testes, 
whereas no effect was observed in those of Nr0b2L–/L– mice (Supple-
mental Figure 4C). This effect was consistent with the deregulation 
of G9a targets genes in the testes of Nr0b2+/+, but not Nr0b2L–/L–, 
mice (Supplemental Figure 4D).
To corroborate the effect of histone modifications directly 
on the G9a target genes, we performed H3K9me1 or H3K9me2 
IP on chromatin extracted from vehicle- or DES-treated mice at 
P10. DES induced a decrease in both H3K9me1 and H3K9me2 
marks on the DNA sequences of G9a target genes 290, 291, 110, 
and Wfdc15a, whereas no effect was observed on the negative con-
trol locus 282 (Figure 7). Surprisingly, for some G9a target genes, 
such as 290 and 110, we noticed a significant increase of H3K9me2 
in Nr0b2L–/L– mice treated with DES compared with vehicle treat-
ment. This effect was opposite to what was observed in Nr0b2+/+ 
mice. In Nr0b2L–/L– mice treated with DES, the higher recruitment 
of H3K9me2 was consistent with the lower expression of some 
G9a target genes, such as 290, 291, 110, and Iap (Figures 6 and 7).
Figure 6
Nr0b2 induces alterations of histone H3K9 marks through the inhibition of G9a, in response to DES. Nr0b2+/+ and Nr0b2L–/L– mice were exposed 
to 0 or 0.75 μg DES. (A and B) Immunoblots of H3K9me1 and H3K9me2 performed on testis (A), and quantification of H3K9me2 and H3K9me2 
accumulation, relative to total H3 (B), of P10 mice (n = 9 per group). (C) Testicular mRNA expression of G9a, normalized to β-actin levels, in 
whole testes of P6 and P10 mice (n = 10–15 per group). (D) Immunoblot of G9a performed on P10 mice (n = 9 per group). Quantification of 
G9a protein accumulation, relative to actin, is also shown. (E) Testicular mRNA expression of G9a target genes Akr1c13, Akr1c12, Chst11, 
Wfdc15a, Mei1, 290, 110, 291, and Iap, normalized to β-actin levels, in whole testes of P10 mice (n = 10–15 per group). Vehicle-treated mice 
were fixed at 100%. *P < 0.05 versus vehicle.
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Nr0b2 is responsible for the cross-talk between DES and the retinoid pathway. 
The analysis of G9a expression in the testes of untreated P10 
Nr0b2+/+ and Nr0b2L–/L– mice showed higher protein accumulation 
in Nr0b2L–/L– mice (Figure 8A), which suggests that G9a is a tar-
get gene of Nr0b2. This was consistent with the higher levels of 
H3K9me1/2 marks and the deregulation of the G9a target genes 
observed in Nr0b2L–/L– mice (Figure 8, B and C).
Retinoids (i.e., all-trans-retinoic acid; RA) are key components that 
induce the entry of germ cells into meiosis (30, 31, 36). We hence 
evaluated the interplay among RA signaling, Nr0b2, and G9a using 
the embryonic teratocarcinoma-derived F9 cell line. This cell line is 
a well-established cell-autonomous model for investigating retinoid 
signaling in vitro, as RA can induce the cells’ differentiation (37). In 
F9 cells, RA treatment led to an increase in G9a mRNA accumula-
tion, which was inhibited by Nr0b2 in a dose-dependent manner 
(Figure 8D). These results were confirmed at the protein level (Fig-
ure 8E), which suggests that Nr0b2 could regulate the expression 
of G9a by inhibiting the RA receptor (Rar) pathway. Using an in 
silico approach based on the Genomatix program (see Methods), 
we mapped a putative Rar response element (RARE) in the promoter 
of G9a. To validate the relevance of this RARE in the regulation of 
G9a expression in response to retinoids, we performed chromatin 
IP (ChIP) experiments using either wild-type or Rarg–/– F9 cells (38). 
Treatment with RA led to a higher level of Rarγ IP on the RARE in 
wild-type cells, whereas no difference was observed in the Rarg–/– F9 
cells (Figure 8F). The potential interaction of Nr0b2 with Rar on the 
promoter of the G9a gene was further substantiated by ChIP experi-
ments using wild-type or Rarg–/– F9 cells transfected with pCMV or 
pCMV-Nr0b2 expression vectors. Consistent with our expression 
data, we found specific enrichment of Nr0b2 on the DNA sequences 
surrounding the RARE of the G9a promoter in wild-type cells, but 
not Rarg–/– F9 cells (Figure 8G), further underscoring the impor-
tance of the Nr0b2/Rar complex in the regulation of G9a.
Discussion
Here, we demonstrated that DES induced abnormalities in the 
male genital tract upon fetal and/or neonatal exposure in mice. In 
animal models, neonatal administration of DES decreased fertility 
in adult male mice as a result of altered morphology of the male 
genital tract, with decreased relative weights of epididymis, vesicle 
seminals, and testis. This was associated with a decrease in epididy-
mis sperm count, which was caused by the increased germ cell death 
we observed in male mice exposed to DES. Interestingly, for all these 
parameters, deficiency for Nr0b2 protected the males exposed to 
DES, which suggests that Nr0b2 plays a critical role in the testicular 
pathophysiology induced by DES. However, we have demonstrated 
that DES acts via several signaling pathways. Through the use of 
estradiol and/or of the Er antagonist ICI, we showed that Nr0b2 
protected the male mice against both estrogenic and nonestro-
genic effects of DES. Even though it is not established in humans, 
these rodent data are the basis of the hypothesis of a potential link 
between these environmental factors (25), including the exposure 
to EDs (39–41), and the fast increase of the incidence of male repro-
ductive disorders (42, 43). Our data could potentially establish a link 
between EDs and male reproductive disorders in humans.
High doses of EDs induce a severe decrease in testicular weight 
caused by germ cell death, which leads to important modifica-
tions in the relative cell type proportions. Such changes could lead 
to false interpretations, because the observed differences in gene 
expression are the result of changes in testicular cell content rather 
Figure 7
Nr0b2 mediates DES-induced alterations of histone H3K9 marks on the promoter of G9a target genes. Shown are results of ChIP of crosslinked 
DNA from testes of P10 Nr0b2+/+ and Nr0b2L–/L– mice using H3K9me1 or H3K9me2 antibodies. The loci studied as G9a targets (290, 291, 110, 
Wfdc15a, and 282) were previously defined and cover at least 1 gene (35). The 282 locus was used as a negative control of H3K9 methylation. 
IgG was used as a negative internal control. For each condition, 6 ChIPs were performed. *P < 0.05 versus vehicle.
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than of the real regulation of gene expression. Through a dose-
effect experiment of DES, we first determined the concentration 
that did not dramatically affect testicular weight. This allowed us 
to assume that at the doses used for the molecular analyses, the 
modifications of gene expression were significant, not the conse-
quences of altered cell content.
Unexpectedly, we observed higher levels of active caspase-3 in 
Nr0b2L–/L– mice compared with Nr0b2+/+ littermates. This increase 
in basal levels of active caspase-3 in Nr0b2L–/L– mice was significant 
in P10 animals (Figure 5C), which could reflect the earlier entry 
in meiosis. In adult mice, we also detected a significant difference 
between active caspase-3 levels in Nr0b2+/+ and Nr0b2L–/L– mice 
(Figure 3C). Interestingly, and in line with our previous studies 
(8), there was no difference in the number of TUNEL-positive 
cells between vehicle-treated Nr0b2+/+ and Nr0b2L–/L– males. The 
increase in active caspase-3 was not consistent with the unchanged 
results of the TUNEL assay and requires further study; this find-
ing reflects the complexity of apoptosis, which can be regulated at 
both activation and inhibition levels.
Even though the present report showed that Nr0b2L–/L– mice were 
protected against the deleterious effect of DES and EB on the male 
reproductive tract, basal estrogen metabolism was similar between 
Nr0b2+/+ and Nr0b2L–/L– males (Supplemental Figure 5, A–C). These 
data suggested that the role of Nr0b2 on the estrogenic pathway is 
only revealed under pathophysiological conditions when exposed 
to estrogenic endocrine disrupters. However, the lack of difference 
between the genotypes under basal condition was surprising and 
difficult to explain; it suggests the existence of some yet-unidenti-
fied compensatory mechanisms. One could speculate that Nr0b1, 
which is very close to Nr0b2 at the structural level, could compen-
sate for the lack of Nr0b2.
Nr0b1 and Nr0b2 are closely related nuclear receptors. More-
over, the impact of Nr0b1 on steroidogenesis has been well dem-
onstrated. In our experiments, however, we have not shown a sig-
Figure 8
Nr0b2 controls G9a expression. (A) G9a immunoblot from whole testes of P10 Nr0b2+/+ and Nr0b2L–/L– untreated mice (n = 5–7 per group). 
Lanes were run on the same gel but were noncontiguous (white line). (B) Immunoblots of H3K9me1 or H3K9me2 performed on P10 Nr0b2+/+ and 
Nr0b2L–/L– mice (n = 6–7 per group). (C) mRNA levels of G9a target genes Defb42, Chst11, 110, 290, Mei1, and Akr1c13 in whole testes of P10 
Nr0b2+/+ and Nr0b2L–/L– mice exposed to 0 or 0.75 μg DES (n = 10–15 per group). (A–C) Levels were normalized to actin, and normalized values 
of Nr0b2+/+ were set at 100%. (D) mRNA expression of Nr0b2 and G9a in F9 cells transfected with 0–800 ng pCMV-Nr0b2 (n = 3). (E) Protein 
accumulation of G9a in F9 cells transfected with pCMV-Nr0b2 in the absence or presence of RA (n = 3). (F and G) ChIP of crosslinked DNA from 
F9 wild-type or Rarg–/– cells using an anti-Rarγ antibody (F) or from F9 wild-type or Rarg–/– cells transfected with pCMV or pCMV-Nr0b2 using 
an anti-Flag antibody (G). Inset: A DNA sequence of ±100 bp covering either the RARE (i) or a sequence 3.0 kb upstream of the RARE (ii) was 
amplified. Results are expressed as fold enrichment over wild-type vehicle-treated cells (F) or over pCMV cells (G) and represent amplification 
variability (n = 4). *P < 0.05 versus vehicle; #P < 0.05 versus next-smallest transfected pCMV-Nr0b2 amount.
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nificant effect of DES treatment on Nr0b1 expression in P10 pups 
(Figure 5F) or in adult males (Figure 4C). These results suggest 
that Nr0b1 is not involved in the DES-induced phenotypes. Sev-
eral studies have shown that Nr0b1 KO mice have normal levels of 
testosterone (44, 45). The Nr0b1 KO mouse phenotype can mostly 
be explained by the altered expression of aromatase, the enzyme 
that synthesizes estrogens, whereas other steroidogenic genes, like 
Star, were not affected (45). Together, these observations imply a 
converging role of both Nr0b members to control full testicular 
steroid metabolism, in which Nr0b2 would predominantly regu-
late steroidogenesis up to the level of testosterone synthesis, and 
Nr0b1 would instead control aromatization.
In adult mice, Nr0b2 was responsible for the DES-induced decrease 
in testosterone production. The absence of a decrease of steroido-
genic genes in Nr0b2L–/L– males after DES exposure is suggestive of 
a major role for Nr0b2 in the DES-induced repression of steroido-
genesis. This hypothesis is further corroborated by the induction 
of Nr0b2 mRNA in response to DES. This effect was also observed 
with EB, which suggests that it might be driven by Nr3a1/2 signal-
ing. This is consistent with previous studies showing that estrogen 
can directly regulate steroidogenesis at the Leydig cell levels (46). 
The ability of estrogen to decrease steroid synthesis in the mouse 
Leydig cell line MA-10, highlighted by the decrease in the mRNAs of 
Star and Cyp11a1, has been described previously (47). To identify the 
possible direct effect of Nr0b2 in Leydig cells following DES admin-
istration, we also performed experiments on MA-10 cells. Similar 
to our in vivo results, EB and DES resulted in an increase of Nr0b2 
mRNA 12 hours after treatment. This increase in Nr0b2 mRNA was 
followed at 24 hours by a significant decrease in Star mRNA. The 
kinetics of the mRNA increase of Nr0b2, followed by the decrease 
of Star mRNA, is consistent with Nr0b2 being a major inhibitor of 
steroidogenesis in Leydig cells. This is consistent with our previous 
work demonstrating that overexpression of Nr0b2 in a Leydig cell 
line represses Star and Cyp11a1 expression and that Nr0b2 binds to 
the promoter of these 2 genes (8). Moreover, our conclusion that 
Nr0b2 controls steroidogenesis directly at the testicular level after 
DES exposure was confirmed by the finding that plasma LH and 
FSH levels were both unaltered by DES as well as Nr0b2 genotype.
At the molecular level, we have previously shown that Nr0b2 
regulates testicular androgen synthesis through repressed mRNA 
expression of 2 activators of steroidogenesis, Nr5a2 and Nr5a1, 
and/or through inhibited transcriptional activities of the same (8). 
Here, the repression of steroidogenesis by Nr0b2 at the lower 0.5-μg 
dose is likely caused by protein-protein interaction, as mRNA 
expression of both Nr5a1 and Nr5a2 was not affected, whereas Star 
accumulation was already reduced at this DES concentration, in 
Nr0b2+/+ mice (data not shown). At the dose of 0.75 μg DES, this 
effect was further amplified, probably by the decreased mRNA 
expression of Nr5a2. Even though Nr5a1 was defined as a target 
gene of Nr0b2, its expression was not affected by DES administra-
tion. The absence of any effect of DES was consistent with previ-
ous studies (15). These data demonstrate the complexity of the 
regulation of Nr5a1, which is known to be controlled by multiple 
factors (48); furthermore, it would be too simplistic to assume that 
the mRNA expression of Nr5a1 is only regulated by Nr0b2.
In contrast to our findings in adult mice (Figure 4), neonatal ste-
roidogenesis seemed not to be controlled by Nr0b2, as Nr0b2L–/L– 
and Nr0b2+/+ mice showed similar profiles (Figure 5, D and E). This 
difference in Leydig cell response seems to occur in parallel with 
the cells’ transition from the fetal to the adult population and is 
in line with the finding that from P20 onward, Nr0b2 becomes 
expressed only in interstitial cells, where it controls steroidogen-
esis (8). Moreover, P10 testis samples showed that Nr0b2 was main-
ly expressed in the tubular compartment of the testis (data not 
shown). This suggests that, at P10, the impact of Nr0b2 following 
DES exposure occurs in the intratubular compartment.
In addition to its role on androgen synthesis in adult mice after 
neonatal DES exposure, Nr0b2 has other functions during postna-
tal testicular development. We administered DES during early post-
natal development, close to the beginning of germ cell differentia-
tion. Indeed, the first spermatocytes are seen at P5 (31). Neonatal 
administration of either DES or EB induced modified expression 
of genes associated with differentiated or undifferentiated cells, 
such as Nanos3, Stra8, and Dmc1. We demonstrated here that DES 
induced accumulation of specific transcripts of undifferentiated 
spermatogonia, specifically in treated Nr0b2+/+ testis, and reduced 
the expression of transcripts involved in germ cell differentiation. 
These results suggest a change of the relative proportion of undiffer-
entiated versus differentiating spermatogonia after DES exposure. 
We thus hypothesize that Nr0b2 mediates the effect of DES on germ 
cell differentiation, which is in line with our previous report that 
Figure 9
Proposed model for the role of Nr0b2 in DES-induced testicular abnor-
malities. Our results indicate that Nr0b2 is a major actor in DES-induced 
testicular pathophysiology. Nr0b2 deficiency counteracts the negative 
effects of DES. In P10 mice, DES induces a blockage in meiosis entry 
and/or progression, which is characterized by the higher expression 
of genes of undifferentiated spermatogonia (Nanos3) and a decrease 
of meiotic genes (Stra8). The effect is stronger in DES-treated males 
compared with males with 1 EB treatment, which could be explained, at 
least in part, by the specific induction of Oct3/4 expression by DES. EB 
and DES treatment alters H3K9me1 and H3K9me2, which are essen-
tial for meiosis progression (29). The impact on histones is driven by 
the lower accumulation of G9a mRNA after DES exposure. This effect 
on meiosis is explained, at least in part, by the lack of the repressive 
activity of Nr0b2 on Rar and retinoid signaling. Finally, in adults, Nr0b2 
inhibits testicular steroidogenesis, on the one hand by inhibiting the 
expression of Nr5a2, which controls the expression of the steroido-
genic genes, and on the other hand by repressing the transcriptional 
activity of Nr5a2 and/or Nr5a1. All these data explain how Nr0b2 plays 
a major role in the subfertility induced by DES exposure.
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Nr0b2L–/L– mice showed earlier differentiation of germ cells than did 
control littermates (8). To understand the alteration of these rela-
tive cell proportions, we analyzed both proliferation and apoptotic 
processes in P10 mouse testes. In contrast to adult mice, this differ-
ential effect observed between Nr0b2+/+ and Nr0b2L–/L– males in early 
postnatal development did not seem to be linked with androgenic 
status. The increased apoptosis observed in Nr0b2+/+ males is most 
likely caused by other alterations. DES treatment clearly affected 
the meiotic cells. In oocytes, DES induced a severe, yet reversible, 
deterioration of meiotic spindle microtubule organization during 
maturation (49). DES reduces viability of Caenorhabditis elegans and 
its fertility, associated with the production of aberrant gametes, as a 
result of nuclear abnormalities and loss of synaptonemal complexes 
(50). Moreover, recent studies have demonstrated the importance 
of germ cell–specific epigenetic processes in the initiation and early 
progression of meiosis (51). Interestingly, mice with a loss-of-func-
tion mutation for H3K9 histone methyltransferases are sterile, with 
germ cells undergoing apoptosis during the pachytene stage (32, 52). 
Several proteins possess H3K9 methyltransferase activity. Suv39h1, 
Suv39h2, and G9a are able to perform H3K9 dimethylation (33), 
whereas only G9a performs H3K9 monomethylation (34). In tes-
tes of DES-treated P10 Nr0b2+/+ mice, we observed decreases in the 
H3K9me1 and H3K9me2 marks, which suggests that DES might 
affect G9a expression and/or activity in the testis. Consistent 
with this hypothesis, G9a mRNA and G9a protein expression was 
decreased in Nr0b2+/+ mice treated with DES. Because of its histone 
methyltransferase activity, G9a acts as a repressor of transcription. 
The decrease of G9a after DES exposure was confirmed in Nr0b2+/+ 
mice by higher mRNA accumulation of known G9a target genes, 
such as Akr1c13 and Chst11 (32). We observed no significant effect 
in the Nr0b2L–/L– mice. It has been recently demonstrated that Nr0b2 
physically interacts with G9a to induce repression of gene expression 
(53, 54). Here, we demonstrated another form of cross-talk between 
Nr0b2 and G9a, in which Nr0b2 inhibited the mRNA expression of 
G9a. It is possible that both coexist and are part of a feedback loop in 
which Nr0b2 inhibits G9a gene expression to attenuate the repres-
sion of their common target genes. The effect of DES on the histone 
methylation marks was also found when we used EB, highlighting 
the involvement of the estrogenic part of DES in this pathway.
If the signaling of G9a was decreased in Nr0b2+/+ mice treated 
with DES, as evidenced by decreased expression of G9a, decreased 
H3K9 methylation, and increased expression of G9a target genes, we 
unexpectedly observed an opposite effect of DES in the Nr0b2L–/L– 
males. Indeed, the expression of some target genes was found more 
repressed in the Nr0b2L–/L– males exposed to DES compared with 
vehicle. This effect, observed in Nr0b2L–/L– males, was confirmed by 
a higher level of methylated histones on the DNA sequences of these 
G9a target genes. This effect is surprising and to date remains unex-
plained. However, this is in line with our conclusion that Nr0b2 par-
ticipates to control G9a signaling. The observed data in Nr0b2L–/L– 
mice treated with DES suggest that the lack of Nr0b2 induced an 
increase in the G9a pathway, or a compensatory pathway through 
other histone methyltransferases. The exact molecular mechanisms 
involved are not established yet and will require further studies.
The molecular mechanisms triggering the initiation of germ cell 
differentiation, in particular the mitotic/meiotic transition, are not 
completely understood. However, retinoids are key components to 
induce entry of germ cells in meiosis (30, 31, 36). Most intriguing-
ly, retinoids have also been shown to induce an increase in H3K9 
methylation during differentiation (55). Based on these reports and 
our above-described findings, we hypothesized that Nr0b2, via the 
control of G9a expression, is the link between RA and DES path-
ways in the control of the meiotic process. This was confirmed by 
the induction of G9a expression following RA administration in 
different cell lines. Moreover, we found a specific enrichment of a 
Rar/Nr0b2 complex on the DNA sequences surrounding the RARE 
of the G9a promoter. Our results therefore show, for the first time 
to our knowledge, a potential interaction between the retinoid sig-
naling pathway and the expression of the histone methyltransferase 
G9a, which could explain, at least in part, the impact of G9a and 
H3K9 methylation in germ cell differentiation.
Interestingly, this effect of DES on germ cell differentiation 
seemed to persist in adult mice, as we observed a clear decrease 
in mRNA accumulation of Stra8 (Supplemental Figure 5D). We 
have indeed demonstrated that the deregulation of G9a was still 
observed at the mRNA and protein levels in Nr0b2+/+ adult males 
treated neonatally with DES (Supplemental Figure 5, E and F). This 
perpetuation of G9a deregulation in adult testis, combined with the 
altered testosterone synthesis, might cooperate to decrease germ 
cell survival and lead to subfertility after DES administration.
It has been previously demonstrated that DES can have estrogenic 
and nonestrogenic effects (15–18). Compared with EB, DES appeared 
to have a stronger effect. To determine the estrogenic part of DES 
activity, we used either a pure estrogenic compound, EB, or the Er 
antagonist ICI. Most of the macroscopic phenotypes observed with 
DES were also obtained using EB (e.g., organ weight, apoptotic pro-
cess), and the Nr0b2L–/L– mice were also protected against the delete-
rious effects of EB (Supplemental Figure 1, B–D, and Supplemental 
Figure 2, B and E). ICI has previously been demonstrated to have del-
eterious effects on the male genital tract (56), with loss of germ cells 
and decrease of fertility. Here, we also observed a significant altera-
tion in sperm count induced by ICI alone (Supplemental Figure 2E). 
In adult rats and mice, treatment with ICI induced effects similar to 
those previously observed in the male reproductive tract of Nr3a1 
KO mice (56–59). These findings suggest that, following ICI treat-
ment, the decrease in sperm concentration in the cauda epididymis 
could be explained, at least in part, by the fact that Nr3a1 is required 
for normal fluid reabsorption, as concluded from studies of Nr3a1 
KO males (60, 61). Most interestingly, ICI partially reversed the effect 
of DES on all the macroscopic testicular abnormalities it induced 
(Supplemental Figure 1F and Supplemental Figure 2F). Notably, we 
used only 1 dose of ICI (50×) to compete with DES; perhaps a higher 
dose would produce even more pronounced competition with DES.
Most of the molecular pathways altered by DES were also found 
to be affected by EB (e.g., testosterone, retinoid pathway). However, 
some of our results highlighted differential effects of DES and EB 
at the dose we used: at P10, the expression of Oct3/4 was changed by 
DES, not by EB. However, this is an important difference, as Oct3/4 
plays an important role in the determination of the pluripotency of 
cells, which could explain why the effect of DES was more potent 
compared with EB. Indeed, the altered expression of Oct3/4 by DES 
might more robustly inhibit germ cell differentiation than that 
by EB. At the molecular level, Nr5a2 has been described to induce 
Oct3/4 expression (62). At P10, the expression of Nr5a2 was not 
affected by DES treatment. This result demonstrated that the effect 
on Oct3/4 expression at P10 age does not seem to be related to the 
status of Nr5a2. On the one hand, differences in dosing and rela-
tive receptor affinity could contribute to the difference in Oct3/4 
expression between DES and EB. Indeed, both compounds have a 
different affinity to either Nr3a1 or Nr3a2, as DES was shown to 
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bind to Ers with a higher affinity than did estradiol (63, 64). On 
the other hand, it could be hypothesized that in response to DES, 
Oct3/4 expression might be regulated by Nr3b1/2/3. DES has pre-
viously been demonstrated to activate Nr3b1/2/3 (13), and these 
receptors positively regulate Oct3/4 expression (14). Even though 
we did not determine the underlying molecular mechanisms, the 
effect of DES on Oct3/4 expression was also inhibited in Nr0b2L–/L– 
mice; therefore, Nr0b2 deficiency might also protect against the 
nonestrogenic effects of DES.
In conclusion, our results demonstrated that Nr0b2 plays a major 
role in the DES signaling pathway, which affects the development and 
function of the male reproductive system. We showed that Nr0b2L–/L– 
male mice were protected against the deleterious effects of DES, as 
they were still able to reproduce even when exposed to high doses of 
DES. This is caused by the multiple actions of Nr0b2 during testicular 
development (Figure 9). First, in neonatal animals, Nr0b2 controls 
germ cell differentiation through inhibition of the retinoid pathway. 
Nr0b2 regulates the expression of genes involved in the entry and pro-
gression of meiosis, such as Stra8 and Nanos3. It also affects meiosis 
through regulation of the expression of the histone methyltransferase 
G9a and the subsequent modification of H3K9 methylation marks. 
These alterations in methylation upon DES exposure induce abnor-
mal chromosomal complexes favoring germ cell apoptosis and could 
affect the meiosis process. Next to these effects, which appear to be 
mediated through the estrogenic pathway, DES seems to inhibit germ 
cell differentiation at P10 through estrogen-independent pathways, 
as shown by Oct3/4 deregulation specifically in DES-treated mice. 
Second, in adult animals, the effect of Nr0b2 was dependent on the 
inhibition of testosterone production, leading to germ cell death. 
Together, our present data define Nr0b2 as one of the major actors in 
the molecular events leading to DES-mediated male infertility.
Methods
Animals. The Nrb02L–/L– mice used were previously described (8) and 
maintained on a mixed background (C57BL/6J/129sv). Mouse treat-
ment protocols are detailed in Supplemental Methods. This study was 
approved by the Institut National de la Santé et de la Recherche Médi-
cale Animal Care Committee.
Histology and immunohistochemistry. H&E and immunohistochemistry 
stainings were performed as described previously (27). See Supplemental 
Methods for details.
Endocrine investigations. Plasma and intratesticular concentrations were 
measured as described previously (27). Testosterone level is expressed as a 
percentage of the vehicle-treated mice for each genotype. See Supplemental 
Methods for details.
Plasma LH and FSH measurements. Plasma concentrations of LH and 
FSH were measured as previously described (65). See Supplemental 
Methods for details.
Real-time PCR. Following testis RNA extraction (TRIzol; Invitrogen) 
and cDNA synthesis (SuperScript II First-Strand Synthesis System; Life 
Technologies), real-time PCR measurement of individual cDNAs was per-
formed using SYBR green dye to measure duplex DNA formation. Primer 
sequences are shown in Supplemental Tables 1 and 2. Results were ana-
lyzed using the Ct method. Quantitative PCR experiments were performed 
as previously described (35). See Supplemental Methods for details.
Western blot. Proteins were extracted using SDS lysis buffer described in 
the ChIP protocol from Upstate (Upstate Biotechnology Inc). See Supple-
mental Methods for details.
Transient transfection. F9 cells (provided by P. Chambon, Institut de Géné-
tique et de Biologie Moléculaire et Cellulaire, Strasbourg, France), were trans-
fected with lipofectamine (Invitrogen). Rar (obtained from C. Rochette-Egly, 
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Strasbourg, 
France) was transfected with increasing amounts of pCMV-Nr0b2 plasmid 
(8). The quantity of DNA was maintained constant by the addition of empty 
pCMV vector. After 24 hours, either 10–6 M RA or vehicle (1:1,000) was added 
to the cells. Cells were harvested 24 hours later, and mRNA or protein extrac-
tions were performed. See Supplemental Methods for details.
TUNEL analysis and Ki-67 staining. TUNEL and Ki-67 experiments were 
performed as described previously (27) on 5 μm of testis fixed in 4% PFA. 
Results are expressed as the number of TUNEL-positive or Ki-67 positive 
cells per 100 seminiferous tubules. See Supplemental Methods for details.
ChIP. In vitro and in vivo ChIP experiments were respectively performed 
from 106 cells, or P10 testis, of 3 mice. ChIP assays were carried out fol-
lowing the protocol provided by the manufacturer (Upstate Biotechnology 
Inc.). See Supplemental Methods for details.
Promoter analysis. To analyze the promoter of G9a, we used the Genomatix 
MatInspector program, which identifies transcription factor binding sites 
in nucleotide sequences using a large library of weight matrices. The analy-
sis of the mouse G9a promoter sequence predicted a potential binding site 
(599–623 nt from the transcription initiation site). Sequence identity was 
CAAGCCATGGGCCACAGGTGAC.
Statistics. For statistical analysis, 2-way ANOVA was performed. When 
significant effects of treatment or genotype or their interactions were 
obtained, multiple comparisons were made with Tukey’s test. All numerical 
data are mean ± SEM. A P value less than 0.05 was considered significant.
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